A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
This study is testing how well an oral medication called upadacitinib works compared to an injection called dupilumab in children with moderate to severe eczema. The goal is to find safe and effective ways to help kids find relief from itchy and inflamed skin when regular creams are not enough.
Children aged 2 to less than 12 years old with moderate to severe eczema that started at least 6 months ago may be able to join. Participants must meet certain weight requirements and have eczema covering at least 10 percent of their body.
Participants will be randomly assigned to receive either daily upadacitinib or dupilumab for a set period of time. Families will visit clinics regularly for check-ups, blood tests, and to share feedback on how well the treatment is working.
This study is currently recruiting patients at various locations worldwide, including sites in cities like Little Rock and Palo Alto in the United States.
- 1Comparing two modern treatments for childhood eczema
- 2Involves regular clinic visits and health check-ups
- 3Open to children between the ages of 2 and 11
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.